1,5-dimethyl citrate | 53798-96-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1,5-dimethyl citrate
• 英文别名: dimethyl citrate；Citronensauredimethylester；2-hydroxy-4-methoxy-2-(2-methoxy-2-oxoethyl)-4-oxobutanoic acid
• CAS: 53798-96-2
• 化学式: C₈H₁₂O₇
• 分子量: 220.179
• InChiKey: XLYPVOJLUJUWKA-UHFFFAOYSA-N

物化性质

• 熔点：
  123-125?C
• 沸点：
  405.1±45.0 °C(Predicted)
• 密度：
  1.378±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于乙腈（少许）、DMSO、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  1,5-dimethyl citrate 在 硫酸 作用下， 生成 1,3-丙酮二羧酸
  参考文献：
  名称：

  Schroeter, Chemische Berichte, 1905, vol. 38, p. 3199

  摘要：

  DOI：
• 作为产物：
  描述：

  3-[[(4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxycarbonyl]-3-hydroxypentanedioic acid 在 盐酸 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 1,5-dimethyl citrate
  参考文献：
  名称：

  通过泡腾片的酸成分将磷酸可待因进行固态酯化。

  摘要：

  发现扑热息痛：可待因泡腾片中的磷酸可待因在室温和37摄氏度下与柠檬酸成分反应形成可待因的柠檬酸酯。在高温下的固态反应中确认了酯化。从光谱数据（核磁共振和质谱法）并通过选择性水解二甲基酯阐明对称和不对称的柠檬酸二甲酯，阐明了三种可能的单取代酯（1-3）的结构。在降解反应中，发现可待因1的对称取代的柠檬酸酯的形成占主导。还发现可用于泡腾片制剂的酒石酸在类似的非溶剂分解反应中与磷酸可待因形成酯。

  DOI：

  10.1002/jps.2600760115

文献信息

• PROCESS FOR PREPARING CEPHALOTAXINE ESTERS
  申请人：Robin Jean-Pierre

  公开号：US20120022250A1

  公开（公告）日：2012-01-26

  A process for preparing cephalotaxine esters corresponding to the following general formula I which comprises the cephalotaxine backbone: C(R 1 )(R 2 )(XH)COO[CTX] wherein CTX represents the cephalotaxine backbone, being optionally substituted and/or dehydrogenated, in which formula I, X is a heteroatom, preferably an oxygen, a sulfur or a nitrogen, R 1 and R 2 , taken separately, may be alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl, heterocycloalkyl or aralkyl groups, said groups being optionally interrupted by ester functions, or groups that can form one or more rings or a heterocycle together, consisting in bringing the corresponding cephalotaxine compound, or salts, isomers or tautomeric forms thereof, which is free or which is in the form of a metal alkoxide corresponding to the following general formula CTXOM, wherein CTX represents the cephalotaxine backbone, being optionally substituted and/or dehydrogenated, in which M is a hydrogen atom or a metal atom, into contact with a heterocyclic side chain precursor having both a bifunctional protected (bidentate) and activated (acylating) form of an acid bearing a hydrogenated heteroatom, in the alpha (α) position with respect to the carboxyl group, and corresponding to the following general formula: in which case W is a carbon, sulfur, silicon or bore atom, X, R 1 and R 2 have respectively the same meaning as above, it being possible for R 1 and R 2 to form a ring or a heterocycle together, and Y and Z are alkyl or heteroalkyl radicals, or monovalent heteroatoms, which may be identical or different, in an independent manner, or may fuse so as to give a divalent heteroatom, it being possible for the X—W bond to be covalent or ionic.

  一种制备对应以下一般式I的头叶松碱酯的方法，其中包括头叶松碱骨架：C(R1)(R2)(XH)COO[CTX]，其中CTX代表头叶松碱骨架，可以是可选择地取代和/或脱氢的，在该式I中，X是一个杂原子，优选为氧、硫或氮，R1和R2，分别取，可以是烷基、环烷基、杂基、芳基、杂芳基、杂环烷基或芳基，这些基团可以通过酯功能团中断，或者可以形成一个或多个环或一个杂环，包括将相应的头叶松碱化合物，或其盐、异构体或互变异构体形式，该化合物是自由的或以金属烷氧基的形式存在，对应以下一般式CTXOM，其中CTX代表头叶松碱骨架，可以是可选择地取代和/或脱氢的，在该式中，M是氢原子或金属原子，与具有双功能保护（双齿）和活化（酰化）形式的酸的α位上带有氢杂原子的杂环侧链前体接触，该酸与羧基相对应，并对应以下一般式：在这种情况下，W是碳、硫、硅或硼原子，X、R1和R2分别具有与上述相同的含义，R1和R2可以共同形成一个环或一个杂环，Y和Z是烷基或杂基基，或一价杂原子，可以独立地相同或不同，或者可以融合以形成二价杂原子，X—W键可以是共价键或离子键。
• Rapid-acting insulin composition comprising a substituted citrate
  申请人：ADOCIA

  公开号：US20170136097A1

  公开（公告）日：2017-05-18

  A composition, in the form of an aqueous solution, including an insulin in hexameric form and at least one substituted citrate of formula I: in which: R 1 , R 2 , R 3 , identical or different, represent OH or AA, at least one of the R 1 , R 2 , R 3 is an AA radical, AA is a radical resulting from a natural or synthetic aromatic amino acid comprising at least one phenyl group or indole group, substituted or not substituted, said AA radical having at least one free carboxylic acid function, and the carboxylic acid functions are in the form of a salt of an alkali metal selected from Na + and K + .

  一种组合物，以水溶液的形式存在，包括六聚体形式的胰岛素和至少一种式I的取代柠檬酸盐：其中：R1、R2、R3，相同或不同，代表OH或AA，R1、R2、R3中至少有一个是AA基团，AA是由天然或合成的芳香氨基酸组成的基团，包括至少一个苯基或吲哚基，取代或未取代，所述AA基团具有至少一个自由羧酸功能基团，羧酸功能基团以Na+和K+中选择的碱金属的盐形式存在。
• [EN] METHOD FOR THE PRODUCTION OF METHYLSUCCINIC ACID AND THE ANHYDRIDE THEREOF FROM CITRIC ACID<br/>[FR] PROCÉDÉ DE PRODUCTION D'ACIDE MÉTHYLSUCCINIQUE ET DE SON ANHYDRIDE À PARTIR D'ACIDE CITRIQUE
  申请人：UNIV LEUVEN KATH

  公开号：WO2018065475A1

  公开（公告）日：2018-04-12

  A process for the preparation of methylsuccinic acid in any form, including its salts, its mono- and diester derivatives and the anhydride thereof, which comprises reacting citric acid or a derivative thereof in decarboxylation conditions, said process comprising (i) reacting citric acid or mono- and diester derivatives thereof in a non- aqueous solvent, specifically excluding alcohols, on a metallic catalyst at a temperature between 50 to 400°C and under a partial hydrogen pressure from 0.1 to 50 bar or (ii) reacting citric acid or any salt thereof or mono-, di- and triester derivatives thereof on a metallic catalyst in solvents comprising at least 5% water, at a temperature of from 50 to 400°C under a hydrogen partial pressure from 0.1 to 400 bar

  一种制备甲基琥珀酸及其盐、单酯和二酯衍生物以及其酐的方法，包括在脱羧条件下反应柠檬酸或其衍生物，所述方法包括(i) 在非水溶剂中在金属催化剂上以50至400°C的温度和0.1至50巴的部分氢压力下反应柠檬酸或其单酯和二酯衍生物，特别排除醇；或(ii) 在含水量至少为5%的溶剂中，在50至400°C的温度下，在0.1至400巴的氢分压下反应柠檬酸或其任何盐或其单酯、二酯和三酯衍生物上。
• CGRP ANALOG
  申请人：Southard George Lee

  公开号：US20110150980A1

  公开（公告）日：2011-06-23

  Sequence modified calcitonin gene related peptide (CGRP) compounds are useful for treating heart failure, stroke, hemorrhagic shock, or migraine, improving renal function, preventing or delaying the advancement of heart failure into advanced stages, treating angina, controlling pulmonary hypertension, counteracting ischemia due to a myocardial infarction, preventing vasospasms during angioplasty, preventing reocclusion of blood vessels during and/or after angioplasty, stent insertion, or the implantation of a vascular grafts, and for treating male impotence and female sexual arousal disorder.

  序列改良的降钙素基因相关肽（CGRP）化合物可用于治疗心力衰竭、中风、出血性休克或偏头痛，改善肾功能，预防或延缓心力衰竭进展至晚期阶段，治疗心绞痛，控制肺动脉高压，对抗心肌梗死引起的缺血，预防在血管成形术期间发生血管痉挛，预防在血管成形术期间和/或之后血管再闭塞，支架植入或血管移植物植入，以及治疗男性阳痿和女性性唤醒障碍。
• [EN] COMBINATION THERAPY<br/>[FR] TRAITEMENT COMBINÉ
  申请人：CARNOT LLC

  公开号：WO2017147220A1

  公开（公告）日：2017-08-31

  The present disclosure provides certain combination therapy technologies that are particularly useful for treating one or more diseases, disorders, or conditions that may be related to abnormal metabolism. In some embodiments, provided technologies provides combinations of TCA cycle acids and ketone bodies. In some embodiments, provided technologies provides combinations of TCA cycle acids and other carboxylic acids.

  本公开提供了一些特定的联合治疗技术，特别适用于治疗可能与异常代谢相关的一种或多种疾病、疾病或症状。在某些实施例中，提供的技术提供了TCA循环酸和酮体的组合。在某些实施例中，提供的技术提供了TCA循环酸和其他羧酸的组合。